Tinidazole

Drug Profile

Tinidazole

Alternative Names: Tindamax

Latest Information Update: 07 Apr 2015

Price : $50

At a glance

  • Originator Presutti Laboratories LLC
  • Developer Mission Pharmacal
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amoebiasis; Amoebic liver abscess; Giardiasis; Trichomoniasis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amoebiasis; Amoebic liver abscess; Bacterial vaginosis; Giardiasis; Trichomoniasis

Most Recent Events

  • 24 May 2007 Registered for Bacterial vaginosis in USA (PO)
  • 17 Aug 2006 Preregistration for Bacterial vaginosis in USA (PO)
  • 17 Aug 2006 Mission Pharmacal has filed a sNDA for a new indication - the treatment of patients with Bacterial vaginosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top